Amrutanjan Health Care Limited has announced that its Board of Directors will convene on Tuesday, February 3, 2026, through video conferencing to deliberate on key financial matters for the third quarter of FY26. The meeting has been scheduled in accordance with Regulation 29(1) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The board meeting will focus on two primary agenda items that are crucial for shareholders and market participants. The directors will review and approve the company's quarterly performance metrics and consider shareholder returns through dividend distribution.

Trading Window Restrictions

The company has implemented mandatory trading restrictions in compliance with regulatory requirements. As previously communicated on December 19, 2025, the trading window for dealing in equity shares remains closed to ensure fair market practices during the financial results announcement period.

Trading Window Timeline

Regulatory Compliance

The trading window closure aligns with the company's Code of Conduct designed to regulate, monitor and report trading in securities. This measure ensures compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, protecting market integrity during sensitive financial disclosure periods.

Stock Exchange Communication

Amrutanjan Health Care Limited has formally notified both major stock exchanges about the upcoming board meeting. The company trades on NSE under the symbol AMRUTANJAN and on BSE with scrip code 590006. The communication was signed by Gagan Preet Singh, General Manager - Legal, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols are followed.

Amrutanjan Health Care , a leading player in the Indian healthcare sector, has reported a solid performance for the second quarter. The company's financial results showcase steady growth and strategic initiatives across its product portfolio.

Financial Highlights

Amrutanjan Health Care posted a 7.08% year-on-year increase in revenue from operations, reaching Rs. 117.70 crores in Q2 compared to Rs. 109.92 crores in the same quarter of the previous year. The company's profitability also saw significant improvements:

• Profit before tax (PBT) grew by 20.51% to Rs. 19.21 crores
• Profit after tax (PAT) increased by 14.23% to Rs. 15.94 crores

For the first half (H1), the company reported:

• Net sales of Rs. 211.75 crores, representing a 9.35% growth
• PBT of Rs. 30.51 crores, showing a substantial increase of 36.88%

Segment Performance

The pain management segment emerged as a key driver of growth for Amrutanjan Health Care:

• Overall pain category grew by 16%
• Body pain category achieved 21% growth

Standout products in the pain management segment included:

• Maha Strong: 31% growth
• Back Pain Roll On: 26% growth
• Head Roll On: 42% growth

Other Business Segments

1. OTC Segment: Generated Rs. 112.80 crores in Q2
2. Beverages Segment: Recorded Rs. 4.29 crores, marking a 26.55% growth
3. Comfy Brand (Women's Hygiene): Sales remained flat at Rs. 32.78 crores due to changes in quantity purchase scheme accounting

Strategic Initiatives

Amrutanjan Health Care has outlined several strategic moves to drive future growth:

1. Product Expansion: Plans to launch premium sanitary pads, targeting the urban and upmarket consumer segment
2. Brand Revival: Reviving the JIFFY analgesic brand with the introduction of a Diclofenac topical range
3. Manufacturing Capacity: A new sanitary napkin plant is expected to be commissioned by late Q4, which should enhance the Comfy brand's profitability and strategic supply

Management Commentary

The company's management highlighted several key points:

1. Implementation of the new GST law in late September impacted quarter-end billing, resulting in some softness in reported top-line figures
2. Efforts to increase chemist channel reach by 100,000 outlets by year-end are showing positive initial results, particularly in P2 markets
3. The company demonstrated operating leverage with profit growth outpacing revenue growth
4. Core strategies include:
   • Market penetration of brand Amrutanjan in P1 markets
   • Market development in P2 markets
   • Product development focus on roll-on formats and newer pain relief products
   • Increasing Comfy brand reach from 0.5 million to 1 million outlets over the next three years
   • Driving digital maturity through SAP, sales force automation, and other integrated applications

Conclusion

Amrutanjan Health Care's Q2 results reflect the company's strong position in the pain management segment and its strategic focus on expanding its product portfolio and market reach. With planned launches in the premium sanitary pad segment and the revival of its JIFFY brand, the company appears well-positioned for continued growth in the coming quarters.

Investors and market watchers will likely keep a close eye on the commissioning of the new sanitary napkin plant and the performance of the company's strategic initiatives in driving future growth and profitability.